Heart Failure Seminar: Focus on HFmrEF Scientific Statement

Heart Failure Seminar: Focus on HFmrEF Scientific Statement - OnDemand

Create Account

Availability

On-Demand

Expires on Jun 04, 2028

Cost

$0.00

Credit Offered

1 CME Credit

1 NCPD Credit

1 CPE Credit

1 AAPA CME Credit

0.1 CEU Credit

Program Overview
Target Audience
Learning Objectives
Faculty
Agenda
Accreditation Statement
Important Dates

Heart failure with mildly reduced ejection fraction (HFmrEF) represents a unique and evolving heart failure phenotype that shares characteristics with both heart failure with reduced (HFrEF) and preserved ejection fraction (HFpEF). To provide clinicians with practical insights into this increasingly recognized patient population, co-authors of the Heart Failure with Mildly Reduced Ejection Fraction: An HFSA Scientific Statement will lead a one-hour seminar exploring the key findings and recommendations from the publication.

During this interactive program, faculty will break down the scientific statement into three focused segments: epidemiology and clinical outcomes, pathophysiology and the overlap/transitional state of HFmrEF, and contemporary treatment strategies.

This seminar offers a unique opportunity to learn directly from the authors and explore the latest evidence shaping HFmrEF care.

This activity is intended for physicians, APPs, nurses, pharmacists, pharmacologists, trainees, fellows.

Following this activity, participants will be better able to:

Describe the epidemiology, clinical characteristics, and outcomes associated with HFmrEF.
Examine the pathophysiologic features of HFmrEF, including its role as an overlap and transitional heart failure phenotype.
Discuss current treatment strategies for patients with HFmrEF.

Jane Wilcox, MD, MSc, FHFSA, Northwestern University Feinberg School of Medicine
Barry Borlaug, MD, Mayo Clinic
Kavita Sharma, MD, Johns Hopkins University School of Medicine
Carolyn Lam, MBBS, PhD, Duke-NUS Medical School, National Heart Centre Singapore
Zachary Cox, PharmD, FHFSA, Lipscomb University College of Pharmacy

Faculty Disclosures

The Heart Failure Society of America (HFSA) is committed to ensuring balance, independence, objectivity, and scientific rigor in its educational activities. HFSA has a disclosure policy that requires oral presenters to disclose all relevant financial relationships for themselves and their spouse or partner during the past 24-months with any commercial entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on patients and related to the content of the activity, whether or not these commercial entities are supporters of the activity.

Speakers will have a disclosure slide at the beginning of each presentation. All potential conflicts of interests have been resolved in accordance with the ACCME Updated Standards for Commercial Support.

The following faculty and/or accreditors with ability to control content for this activity have no conflict of interest:

Shauna Wheeler, MSL (CE Reviewer

The following faculty and/or accreditors with ability to control content for this activity have listed the below disclosures:

Barry Borlaug - Consultant: Aria, Boehringer Ingelheim, BridgeBio Pharmacy, INC, Edwards LifeSciences, Eli Lilly, Janssen, Merck, Merck, NGMBio, Novo Nordisk, ShouTi, VADovations, Amgen (Ended); Research Support: AstraZeneca, Axon, Corvia Medical, DoD, Medtronic, NIH/NHLBI, Novo Nordisk, Rivus Pharmaceuticals, Tenax Therapeutics, GlaxoSmithKline (Ended), Mesoblast (Ended)
Zachary Cox - Consultant: Kestra Medical Technologies, Reprieve Cardiovascular, Roche, Vectorious, WhiteSwell, ABIOMED (Ended), Lexicon Pharmaceuticals (Ended); Research Support: Translational Catalyst, AstraZeneca (Ended), Cumberland Pharmaceuticals (Ended)
Carolyn Lam - Alnylam Pharmaceuticals, AnaCardio, Applied Therapeutics, AstraZeneca, Bayer AG, Boehringer Ingelheim, Boston Scientific, BridgeBio Pharma, Corteria, CPC Clinical Research, Cytokinetics, Eli Lily, EvlaBio AG, ICON Clinical Research, Impulse Dynamics, Intellia Therapeutics, Janssen, Klyv Therapeutics, Medscape/WebMD, Global, Merck, Novartis, Novo Nordisk, Pfizer, Radcliffe Group Ltd, Ribocure Pharmaceuticals, Roche, Tenax Therapeutics, Us2.ai; Co-Founder: Us2.ai; Research Support: Novo Nordisk, Roche
Kavita Sharma - Advisory Panel: Alleviant Medical, Bristol-Myers Squibb, Novartis, RIVUS, Janssen (Ended); Consultant: AstraZeneca, Bayer AG, Edgewise Therapeutics, Edwards LifeSciences, Imbria, Novartis, Novo Nordisk; Research Support: Amgen

Off Label Disclosure
This CME activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME activity is for continuing medical education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options for a specific patient’s medical condition.

Epidemiology & Outcomes

Jane Wilcox, MD, MSc, FHFSA

Overlap Transition State/Pathophysiology

Speaker Name

Treatment (Panelists)

Jane Wilcox, MD, MSc, FHFSA, Northwestern University Feinberg School of Medicine
Barry Borlaug, MD, Mayo Clinic
Kavita Sharma, MD, Johns Hopkins University School of Medicine
Carolyn Lam, MBBS, PhD, Duke-NUS Medical School, National Heart Centre Singapore
Zachary Cox, PharmD, FHFSA, Lipscomb University College of Pharmacy

In support of improving patient care, The Heart Failure Society of America is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

The Heart Failure Society of America designates this live activity for a maximum of 1.00 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This educational activity is approved for nursing continuing professional development (NCPD) units by the Heart Failure Society of America. This activity is approved for a maximum of 1.00 contact hours.

The Heart Failure Society of America is an accredited provider of continuing pharmacy education (CPE). This event is accredited for up to 1.00 contact hours of knowledge-based CPE. ACPE Universal Activity Numbers (UAN): JA4008267-0000-26-005-L01-P (live); JA4008267-0000-26-006-H01-P (home study)

The Heart Failure Society of America has been authorized by the American Academy of Physician Associates (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.00 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.

This activity is approved for 1.00 contact hours (0.10 CEUs) of general continuing education for health care professionals.

Successful completion of this activity includes the completion of the post-course evaluation.

Originally recorded July 22, 2026